A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.
A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis
Sponsor: Kowa Research Institute, Inc.
Listed as NCT06525311, this PHASE1 trial focuses on Compensated Cirrhosis and Primary Biliary Cholangitis and remains completed. Sponsored by Kowa Research Institute, Inc., it has been updated 8 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 3 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kowa Research Institute, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .